Request initial doses ERVEBO®

ERVEBO® is approved by FDA for prevention of Ebola virus disease (EVD) in people 18 years of age and older. Pre-exposure vaccination with ERVEBO is recommended for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus (species Zaire ebolavirus, or EBOV) because they are:

  • EVD responders: Individuals responding to an EBOV outbreak.
  • Biosafety level 4 (BSL-4) workers: Laboratorians and support staff working at BSL-4 facilities with replication-competent EBOV or with specimens suspected to contain replication-competent EBOV. Personnel working at Laboratory Response Network facilities may be eligible to receive ERVEBO depending on specific circumstances of public health needs and the Ebola preparedness and/or response activities at such facilities.
  • Healthcare personnel (HCP): HCP at federally designated Special Pathogens Treatment Centers involved in the care and transport of patients infected or suspected to be infected with EBOV. HCP working at state-designated Ebola healthcare facilities or other facilities may be eligible to receive ERVEBO depending on specific circumstances of public health needs and the Ebola preparedness and/or response activities at such facilities.

ERVEBO is not planned for commercial marketing but is maintained in the Strategic National Stockpile (SNS) with vaccine access within the United States facilitated by the U.S. government. The Centers for Disease Control and Prevention will provide ERVEBO when requested by licensed healthcare providers from institutions or sites with individuals who meet the eligibility criteria included in the 2020 ACIP recommendations.

Licensed healthcare providers interested in initial doses of ERVEBO for patients that meet the eligibility criteria should send an email to spathvax@cdc.gov with subject line: Request for ERVEBO. The CDC Ebola Vaccine Program will respond with the required instructions and forms for eligible requests.

The duration of protection conferred by an initial dose of ERVEBO is unknown. Clinicians may be able to request booster doses for eligible individuals who were previously vaccinated (e.g., ≥ 6 months since prior vaccination) under an expanded access IND protocol.